LPAR2 is a G-protein-coupled receptor for lysophosphatidic acid (LPA) that mediates diverse physiological and pathological processes through coupling to Gi/o, G12/13, and Gq protein families 1. The receptor activates phospholipase C and downstream signaling cascades including PI3K-Akt, Raf1-Erk, and PKD1-CD36 pathways 1. In cardiovascular pathology, LPAR2 plays a protective role during myocardial infarction by promoting endothelial cell proliferation and angiogenesis while maintaining vascular homeostasis; Lpar2 knockout mice exhibited increased vascular leak, larger infarct scars, and impaired cardiac recovery 1. LPAR2 demonstrates bidirectional roles in pruriception, with central LPAR2 suppressing hydroxychloroquine-evoked itch, contrasting peripheral LPAR5 activation 2. In cancer progression, elevated LPAR2 expression correlates with poor prognosis in head and neck squamous cell carcinoma and renal cell carcinoma through activation of MAPK/NF-κB signaling and β-catenin pathways, promoting proliferation, migration, and altered energy metabolism 345. Additionally, LPAR2 contributes to preeclampsia pathogenesis via a circ_0007611/miR-34c-5p regulatory axis that suppresses trophoblast apoptosis 6, and represents a therapeutic target in rheumatoid arthritis through NF-κB/MAPK modulation 7. LPAR2 variants associate with metabolic dysfunction-associated steatotic liver disease susceptibility 8.